Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CV6-168,Fluorouracil
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CV6 Therapeutics Doses First Patient in Phase 1a Study of dUTPase Inhibitor CV6-168
Details : CV6-168 is a first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase. It is being investigated in combination with fluorouracil in cancer patients.
Product Name : CV6-168
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 15, 2024
Lead Product(s) : CV6-168,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CV6-168,Fluorouracil
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CV6 Therapeutics Receives MHRA Approval for Novel Cancer Therapy Phase 1a Clinical Trial
Details : CV6-168 is a first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase.
Product Name : CV6-168
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 14, 2023
Lead Product(s) : CV6-168,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable